v3.26.1
Agreements with Royalty Pharma - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jan. 07, 2022
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Arrangement consideration of debt transaction $ 150,000                  
Short term accrued liabilities   $ 76,862         $ 76,862   $ 83,278  
Liabilities   2,098,038         2,098,038   2,084,162  
RP Aficamten RPA, RPI ICAV [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Short term accrued liabilities   1,300         1,300      
RP OM Loan Agreement [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Change in fair value of liabilities   (2,100) $ 1,800 $ 14,300 $ (3,600)          
RP OM Loan Agreement And RP Ulacamten RPA [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Change in fair value of liabilities   $ 2,400   $ 14,600     $ 800 $ 10,700    
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]             Liabilities, Fair Value Adjustment      
RP OM Loan Agreement And RP Ulacamten RPA [Member] | Maximum [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Percentage of discount rates for fair values of derivative liabilities   17.00%   18.00%     17.00% 18.00%    
RP OM Loan Agreement And RP Ulacamten RPA [Member] | Minimum [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Percentage of discount rates for fair values of derivative liabilities   14.00%   10.00%     12.00% 10.00%    
RP Multi Tranche Loan [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Additional embedded derivatives recognized   $ 30,700 $ 29,600 $ 17,600 $ 11,700   $ 30,700 $ 17,600 $ 31,100 $ 11,300
Percentage of probability of default of derivative liabilities             10.00%      
RP Multi Tranche Loan [Member] | Maximum [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Percentage of discount rates for fair values of derivative liabilities   15.00%   12.00%     15.00% 14.00%    
RP Multi Tranche Loan [Member] | Minimum [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Percentage of discount rates for fair values of derivative liabilities   14.00%   10.00%     12.00% 10.00%    
2022 Royalty Pharma Transactions [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Milestone payment 50,000                  
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Upfront payment 50,000                  
Imputed rate of interest on unamortized portion of liability   26.10%   20.50%     26.10% 20.50%    
2022 Royalty Pharma Transactions [Member] | RP Multi Tranche Loan [Member] | Term Loan Tranche 1 Tranche 4 Tranche 5 and Tranche 6 [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Estimated fair value of long term debt   $ 259,300         $ 259,300      
2024 RPI Transactions [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Additional carrying value           $ 33,300        
Royalty Purchase Finance Trust Agreement [Member] | RP OM RPA [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Imputed rate of interest on unamortized portion of liability   0.00%   0.10%     0.00% 0.10%    
Non-cash interest expense recognized             $ 92,300      
CRL Option [Member] | RP Multi Tranche Loan [Member] | Term Loan Tranche 7 [Member]                    
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]                    
Term loan, maximum borrowing capacity $ 175,000